Shares of Amarin Corporation (AMRN) have risen by 20% since my initial article on the company back in May, in which I told readers to expect a run up shortly. While shares did increase by almost half at one point, the stock has come back down although it remains in an uptrend.
AMRN data by YCharts
Keys to the original bullish thesis included the following:
Prescription growth for the company’s primary asset, Vascepa, had grown 50% every quarter for the past three quarters. Management projected $155 million to $165 million in 2017 revenue, while weekly scripts continued....More>>>